Effect of genetic modifications in the synaptic dopamine clearance systems on addiction-like behaviour in mice

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 1, 2011, Pages 2-8

  Tammimäki, Anne ^a   Männistö, Pekka T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE TRANSPORTER; NICOTINE; OPIATE DERIVATIVE; PSYCHOSTIMULANT AGENT; VESICULAR MONOAMINE TRANSPORTER 2;

ADDICTION; ALCOHOLISM; DNA MODIFICATION; GENE MUTATION; KNOCKOUT MOUSE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SYNAPSE; TOBACCO DEPENDENCE;

ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; MALE; MICE; MICE, KNOCKOUT; MONOAMINE OXIDASE; MUTATION; SYNAPSES; SYNAPTIC TRANSMISSION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

MUS;

EID: 78650205616     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00647.x     Document Type: Review

References (69)

1. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006;29:565-98.
2. Schultz W. Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 2006;57:87-115.
3. Ito R, Robbins TW, Everitt BJ. Differential control over cocaine-seeking behavior by nucleus accumbens core and shell. Nat Neurosci 2004;7:389-97.
4. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998;28:309-69.
5. Cador M, Bjijou Y, Stinus L. Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine. Neuroscience 1995;65:385-95.
6. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003;168:3-20.
7. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci 2006;7:464-76.
8. Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007;30:220-7.
9. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-13.
10. Koob GF, Le Moal M. Neurobiology of Addiction. Elsevier, Amsterdam, 2006.
11. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1998;1:132-7.
12. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H et al. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 2004;29:1790-9.
13. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-12.
14. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 1998;95:7699-704.
15. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci USA 2001;98:5300-5.
16. Spielewoy C, Gonon F, Roubert C, Fauchey V, Jaber M, Caron MG et al. Increased rewarding properties of morphine in dopamine-transporter knockout mice. Eur J Neurosci 2000;12:1827-37.
17. Spielewoy C, Biala G, Roubert C, Hamon M, Betancur C, Giros B. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology 2001;159:2-9.
18. Hironaka N, Ikeda K, Sora I, Uhl GR, Niki H. Food-reinforced operant behavior in dopamine transporter knockout mice: enhanced resistance to extinction. Ann NY Acad Sci 2004;1025:140-5.
19. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 2001;98:1982-97.
20. Salahpour A, Medvedev IO, Beaulieu JM, Gainetdinov RR, Caron MG. Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals. Biol Psychiatry 2007;61:65-9.
21. Cagniard B, Balsam PD, Brunner D, Zhuang X. Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 2006;31:1362-70.
22. Peciña S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 2003;23:9395-402.
23. Donovan DM, Miner LL, Perry MP, Revay RS, Sharpe LG, Przedborski S et al. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Brain Res Mol Brain Res 1999;73:37-49.
24. Salahpour A, Ramsey AJ, Medvedev IO, Kile B, Sotnikova TD, Holmstrand E et al. Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc Natl Acad Sci USA 2008;105:4405-10.
25. Chen R, Han DD, Gu HH. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J Neurochem 2005;94:352-9.
26. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S et al. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 2006;103:9333-8.
27. Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, Gainetdinov RR. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 2005;3:e271.
28. Budygin EA, Brodie MS, Sotnikova TD, Mateo Y, John CE, Cyr M et al. Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc Natl Acad Sci USA 2004;101:7781-6.
29. Carboni E, Spielewoy C, Vacca C, Nosten-Bertrand M, Giros B, Di Chiara G. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci 2001;21:RC141.
30. Mateo Y, Budygin EA, John CE, Jones SR. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc Natl Acad Sci USA 2004;101:372-7.
31. Budygin EA, John CE, Mateo Y, Jones SR. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice. J Neurosci 2002;22:RC222.
32. Tilley MR, Cagniard B, Zhuang X, Han DD, Tiao N, Gu HH. Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression. BMC Neurosci 2007;8:42.
33. Thomsen M, Hall FS, Uhl GR, Caine SB. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J Neurosci 2009;29:1087-92.
34. Thomsen M, Han DD, Gu HH, Caine SB. Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. J Pharmacol Exp Ther 2009;331:204-11.
35. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI et al. Amphetamine, 3, 4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001;60:1181-8.
36. Weiss S, Tzavara ET, Davis RJ, Nomikos GG, Michael McIntosh J, Giros B et al. Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice. Neuropharmacology 2007;52:1496-508.
37. Weiss S, Nosten-Bertrand M, McIntosh JM, Giros B, Martres MP. Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance. Neuropsychopharmacology 2007;32:2465-78.
38. Mathews TA, John CE, Lapa GB, Budygin EA, Jones SR. No role of the dopamine transporter in acute ethanol effects on striatal dopamine dynamics. Synapse 2006;60:288-94.
39. Savelieva KV, Caudle WM, Findlay GS, Caron MG, Miller GW. Decreased ethanol preference and consumption in dopamine transporter female knock-out mice. Alcohol Clin Exp Res 2002;26:758-64.
40. Morice E, Denis C, Giros B, Nosten-Bertrand M. Evidence of long-term expression of behavioral sensitization to both cocaine and ethanol in dopamine transporter knockout mice. Psychopharmacology 2010;208:57-66.
41. Hall FS, Sora I, Uhl GR. Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 2003;28:620-8.
42. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94:9938-43.
43. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997;19:1285-96.
44. Savelieva KV, Caudle WM, Miller GW. Altered ethanol-associated behaviors in vesicular monoamine transporter heterozygote knockout mice. Alcohol 2006;40:87-94.
45. Fukushima S, Shen H, Hata H, Ohara A, Ohmi K, Ikeda K et al. Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology 2007;193:55-62.
46. Uhl GR, Li S, Takahashi N, Itokawa K, Lin Z, Hazama M et al. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J 2000;14:2459-65.
47. Gainetdinov RR, Sotnikova TD, Caron MG. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 2002;23:367-73.
48. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995;268:1763-6.
49. Popova NK, Gilinskii MA, Amstislavskaya TG. Effect of monoamine oxidase gene knockout on dopamine metabolism in mouse brain structures. Bull Exp Biol Med 2004;137:382-4.
50. Agatsuma S, Lee M, Zhu H, Chen K, Shih JC, Seif I et al. Monoamine oxidase A knockout mice exhibit impaired nicotine preference but normal responses to novel stimuli. Hum Mol Genet 2006;15:2721-31.
51. Popova NK, Vishnivetskaya GB, Ivanova EA, Skrinskaya JA, Seif I. Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: a comparison with effects of MAO A inhibitor clorgyline. Pharmacol Biochem Behav 2000;67:719-27.
52. Kim JJ, Shih JC, Chen K, Chen L, Bao S, Maren S et al. Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice. Proc Natl Acad Sci USA 1997;94:5929-33.
53. Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, Adams JD et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 1997;17:206-10.
54. Chen L, He M, Sibille E, Thompson A, Sarnyai Z, Baker H et al. Adaptive changes in postsynaptic dopamine receptors despite unaltered dopamine dynamics in mice lacking monoamine oxidase B. J Neurochem 1999;73:647-55.
55. Lee M, Chen K, Shih JC, Hiroi N. MAO-B knockout mice exhibit deficient habituation of locomotor activity but normal nicotine intake. Genes Brain Behav 2004;3:216-27.
56. Holschneider DP, Scremin OU, Chen K, Shih JC. Lack of protection of monoamine oxidase B-deficient mice from age-related spatial learning deficits in the Morris water maze. Life Sci 1999;65:1757-63.
57. Yin HS, Chen K, Kalpana S, Shih JC. Differential effects of chronic amphetamine and baclofen administration on cAMP levels and phosphorylation of CREB in distinct brain regions of wild type and monoamine oxidase B-deficient mice. Synapse 2006;60:573-84.
58. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 2002;15:246-56.
59. Huotari M, Garcia-Horsman JA, Karayiorgou M, Gogos JA, Männistö PT. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology 2004;172:1-10.
60. Yavich L, Forsberg M, Gogos JA, Karayiorgou M, Männistö PT. Site specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 2007;27:10196-202.
61. Haasio K, Huotari M, Nissinen E, Männistö PT. Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. J Appl Toxicol 2003;23:213-9.
62. Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 2008;28:8709-23.
63. Babovic D, O'Tuathaigh CM, O'Connor AM, O'Sullivan GJ, Tighe O, Croke DT et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 2008;155:1021-9.
64. Suzuki G, Harper KM, Hiramoto T, Funke B, Lee M, Kang G et al. Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Hum Mol Genet 2009;18:3914-25.
65. Huotari M, Santha M, Lucas LR, Karayiorgou M, Gogos JA, Männistö PT. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther 2002;303:1309-16.
66. Tammimäki A, Forsberg MM, Karayiorgou M, Gogos JA, Männistö PT. Increase in free choice oral ethanol self-administration in catechol-O-methyltransferase gene-disrupted male mice. Basic Clin Pharmacol Toxicol 2008;103:297-304.
67. Tammimäki A. Roles of Forced Nicotine Exposure and Comt Gene Disruption in the Development of Addiction-Related Behavioural and Neurochemical Changes in Mice. Division of Pharmacology and Toxicology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland, 2008.
68. Grice DE, Reenilä I, Männistö PT, Brooks AI, Smith GG, Buxbaum JD et al. Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. BMC Genomics 2007;8:76.
69. Kambur O, Männistö PT, Viljakka K, Reenilä I, Lemberg K, Kontinen VK et al. Stress-induced analgesia and morphine responses are changed in catechol-O-methyltransferase-deficient male mice. Basic Clin Pharmacol Toxicol 2008;103:367-73.